Bioventix Plc engages in the development and supply of antibodies. It is involved in the development and manufacture of sheep monoclonal antibodies for use in the fields of clinical diagnostics and drugs of abuse testing. The company was founded on October 7, 2003 and is headquartered in Farnham, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company